ArticleFoods (Basel, Switzerland)2025
Highly Sensitive Lateral Flow Immunoassay for Clenbuterol and Structurally Similar Beta2-Agonists in Meat.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Beta-agonists are growth promoters sparking considerable interest in animal husbandry. However, their numerous negative effects on health have led to a number of restrictions on their presence in agricultural products, which differ depending on the type of preparation and food. In this regard, there is a demand for methods of their mass, rapid, and easy control with strict, focused selectivity. In this paper, a lateral flow immunoassay (LFIA) with clenbuterol (CLE), a priority β2-agonist for food safety, as the main target compound is proposed. The LFIA is based on indirect labeling of specific antibodies by gold nanoparticles via anti-species antibodies. The development of the LFIA involved optimizing the concentrations of immunoreagents and the composition of the reaction mixture (buffer type and pH, ionic strength, detergents, and additional components). In qualitative (visual) mode, the LFIA detects up to 1.0 ng/mL of CLE. In quantitative mode, the detection limit reaches 0.02 ng/mL, surpassing previously described colorimetric LFIAs. The selectivity of the obtained and used monoclonal antibodies allows for the group-specific detection of CLE and structurally close (the presence of a trimethyl residue, similar charge distribution in the benzene ring) common β2-agonists-salbutamol and mabuterol-distinguishing them from other β-agonists, including the widely used β1-agonist ractopamine, which differs in application and biological activity. The assay time is 15 min. The application of the LFIA for meat samples demonstrated that the CLE recovery ranged between 86% and 104%. The obtained results confirm the effectiveness and competitive potential of the developed assay for screening meat products outside of laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.